Aqueous ophthalmic solutions of phentolamine and medical uses thereof
The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
1. An aqueous ophthalmic solution consisting of:
a. 1% (w/v) of phentolamine or a pharmaceutically acceptable salt thereof;
b. 1% (w/v) to 6% (w/v) of at least one polyol compound having a molecular weight less than 250 g/mol;
c. 0.1 mM to 10 mM of at least one buffer;
d. water; and
e. optionally one or more of an alkali metal halide or alkaline earth metal halide;
wherein the solution has a pH in the range of 4.0 to 7.5.
2. The solution of claim 1 , wherein
the at least one polyol compound is mannitol.
3. The solution of claim 1 , wherein
the buffer comprises sodium acetate.
4. The solution of claim 1 , wherein the solution has a pH in the range of 4.5 to 6.0.
5. An aqueous ophthalmic solution, consisting of:
a. 1% (w/v) phentolamine mesylate;
b. 1% (w/v) to 6% (w/v) mannitol;
c. 0.1 mM to 10 mM of at least one buffer;
d. water; and
e. optionally one or more of an alkali metal halide or alkaline earth metal halide;
wherein the solution has a pH in the range of 4.5 to 6.0.
6. The solution of claim 5 , wherein the mannitol is present at a concentration of 4% (w/v).
7. The solution of claim 5 , wherein the solution has a pH in the range of 4.5 to 5.5.
8. The solution of claim 6 , wherein the solution has a pH in the range of 4.5 to 5.5.
9. The solution of claim 5 , wherein the buffer is present at a concentration in the range of 2 mM to 4 mM.
10. The solution of claim 6 , wherein the buffer is present at a concentration in the range of 2 mM to 4 mM.
11. The solution of claim 8 , wherein the buffer is present at a concentration in the range of 2 mM to 4 mM.
12. The solution of claim 5 , wherein the buffer is present at a concentration of 3 mM.
13. The solution of claim 6 , wherein the buffer is present at a concentration of 3 mM.
14. The solution of claim 8 , wherein the buffer is present at a concentration of 3 mM.
15. The solution of claim 5 , wherein the buffer comprises sodium acetate.
16. The solution of claim 6 , wherein the buffer comprises sodium acetate.
17. The solution of claim 7 , wherein the buffer comprises sodium acetate.
18. The solution of claim 8 , wherein the buffer comprises sodium acetate.
19. The solution of claim 11 , wherein the buffer comprises sodium acetate.
20. The solution of claim 14 , wherein the buffer comprises sodium acetate.
21. The solution of claim 5 , wherein less than 2% of the phentolamine mesylate degrades upon storage at 25° C. for 24 weeks.
22. The solution of claim 20 , wherein less than 2% of the phentolamine mesylate degrades upon storage at 25° C. for 24 weeks.